A second-generation CD33-directed CAR construct comprising lintuzumab-CD28/CD3ζ306 has demonstrated promising outcomes in a Phase 1/2 dose-escalation interim analysis of children, adolescents, and young adults with R/R AML (NCT03971799). Here, CD33 is linked to acute myeloid leukemia.